|
|
Baseline (T0) |
After 9 months of treatment (T3)
|
| ID |
Subtypes |
NRTI |
NNRTI |
PI |
NRTI |
NNRTI |
PI |
|
Patients with baseline drug resistance mutations who did not fail |
| GT2026 |
CRF02_AG |
K219E |
0 |
0 |
- |
- |
- |
| GT2035 |
CRF13_CPX |
L210W |
0 |
0 |
- |
- |
- |
| GT2042 |
CRF06_CPX |
T215A |
0 |
0 |
- |
- |
- |
| GT2044 |
C |
K219E |
0 |
0 |
- |
- |
- |
| GT2045 |
CRF06_CPX |
L210W |
0 |
L10I |
- |
- |
- |
| PG1005 |
CRF02_AG |
T215A |
0 |
0 |
- |
- |
- |
| Patients with baseline drug resistance mutations who failed |
| GT2052 |
CRF02_AG |
0 |
V108I |
0 |
G335D, M184V |
K101E, V108I, G190A |
0 |
| CE3008 |
CRF02_AG |
0 |
K103N |
0 |
ND |
ND |
ND |
| CE3012 |
CRF02_AG |
D67N, K219E |
0 |
0 |
D67N, K219E |
0 |
0 |
| CE3027 |
CRF06_CPX |
G335D |
V179E |
0 |
0 |
V179E |
0 |
| CE 129 |
CRF02_AG |
G335D, A371V, T69N |
0 |
0 |
G335D |
|
L10V |
| Patients without baseline drug resistance mutations who failed |
| GT2014 |
CRF02_AG |
0 |
0 |
0 |
0 |
0 |
0 |
| GT2018 |
CRF02_AG |
0 |
0 |
0 |
0 |
0 |
0 |
| GT2038 |
A1 |
G335D, A371V |
0 |
0 |
0 |
0 |
0 |
| CE3049 |
CRF09_CPX |
0 |
0 |
L10I |
G335D, A371V |
0 |
L10I |
| CE3080 |
CRF02_AG |
G335D |
0 |
0 |
M184V |
K103N |
0 |
| CE3094 |
CRF02_AG |
0 |
0 |
L90I, L10V |
G335D, A371V, M184V |
Y181C |
L90I |
| CE3128 |
CRF02_AG |
G335DA371V |
0 |
L10V |
M184V |
K101Q, K103N |
L10V |
| CE3131 |
CRF02_AG |
G335D |
0 |
L10V |
M184V |
Y181C |
L10V |
| GT2043 |
CRF02_AG |
0 |
0 |
0 |
M184V |
Y181C |
L10V |
| GT2001 |
CRF02_AG |
0 |
0 |
0 |
ND |
ND |
ND |
| GT2009 |
CRF02_AG |
0 |
0 |
0 |
ND |
ND |
ND |
| CE3003 |
CRF02_AG |
0 |
0 |
L10I |
ND |
ND |
ND |
| PG1019 |
CRF02_AG |
0 |
0 |
L10V |
ND |
ND |
ND |
|
